STVN
Stevanato Group S.p.A.
$18.00
-2.49%
$5.5B
No data for this timeframe.
Vol
Market Cap$5.5B
Cap SizeMid Cap
SEC Reports1
Recent Activity
May 11, 2026
SEC
Stevanato Group filed a 6-K containing the explanatory report for its ordinary and extraordinary shareholders meeting on
6-K — Impact 3/10
May 7, 2026
earnings_calendar
STVN Q1 2026 Earnings Before Market Open — 2026-05-07
Mar 18, 2026
Event
Disopyramide Phosphate
Mortality In the National Heart, Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CA
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$24.39 (Mar 2026)
Current $18.10
Low $17.50
Median $25.00
High $32.00
9 analysts
$17.50
$32.00
Analyst Ratings
7Strong Buy
6Buy
4Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 6, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight → Equal-Weight |
| Mar 5, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 5, 2026 | Keybanc | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.15 ▼ -2.4% | $0.14 — $0.17 | 17% YoY | 10 |
| Next Q | $0.19 ▼ -1.1% | $0.17 — $0.20 | 16% YoY | 9 |
| Current FY | $0.71 ▲ +0.9% | $0.69 — $0.73 | 13% YoY | 10 |
| Next FY | $0.84 ▼ -1.6% | $0.79 — $0.89 | 18% YoY | 10 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 3.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Mar 2026): 76% buy across 17 analysts — 7 strong buy, 6 buy, 4 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$24.39 mean target (Mar 2026)
$17.50 Low
$32.00 High
| Metric | Value |
|---|---|
| Current Price | $18.10 |
| Target Low | $17.50 |
| Target Mean | $24.39 |
| Target Median | $25.00 |
| Target High | $32.00 |
| # Analysts | 9 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.15 | $0.14 | $0.17 | 17.5% | -2.4% | 3↑ 4↓ | $0.3B | 6.6% | 10 |
| Next Q 2026-09-30 |
$0.19 | $0.17 | $0.20 | 15.5% | -1.1% | 6↑ 2↓ | $0.3B | 7.4% | 9 |
| Current FY 2026-12-31 |
$0.71 | $0.69 | $0.73 | 13.3% | +0.9% | 9↑ 1↓ | $1.3B | 7.5% | 10 |
| Next FY 2027-12-31 |
$0.84 | $0.79 | $0.89 | 18.5% | -1.6% | 4↑ 6↓ | $1.4B | 9.8% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.149 | |
| 7d ago | $0.150 | -0.000 |
| 30d ago | $0.153 | -0.004 |
| 60d ago | $0.155 | -0.006 |
| 90d ago | $0.166 | -0.017 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 6, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Mar 5, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 5, 2026 | Keybanc | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 6 | 4 | 0 | 0 | 76% | |
| May 1, 2026 | 7 | 6 | 4 | 0 | 0 | 76% | |
| Apr 1, 2026 | 7 | 6 | 4 | 0 | 0 | 76% | |
| Mar 1, 2026 | 7 | 6 | 4 | 0 | 0 | 76% | |
| Feb 1, 2026 | 7 | 6 | 4 | 0 | 0 | 76% | |
| Jan 1, 2026 | 7 | 6 | 4 | 0 | 0 | 76% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 7, 2026
earnings_calendar
STVN Q1 2026 Earnings Before Market Open — 2026-05-07
Mar 18, 2026
FDA
Disopyramide Phosphate
Mortality In the National Heart, Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multi-center, randomized, double
Mar 13, 2026
Clinical Trial
Bupivacaine Alone vs Bupivacaine With Tramadol in Local Anesthesia Procedures
Phase Phase 3 — COMPLETED
Mar 4, 2026
earnings_calendar
STVN Q4 2025 Earnings After Market Close — 2026-03-04